Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis

References

• HeeschenCDimmelerSHammCWSoluble CD40 ligand in acute coronary syndromesN Engl J Med20033481104111112646667
   PubMed Web of Science ®Google Scholar
• RoyleNJIrwinDMKoschinskyMLMacGillivrayRTHamertonJLHuman genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectivelySomat Cell Mol Genet1987132852923474786
   PubMedGoogle Scholar
• CoughlinSRThrombin signalling and protease-activated receptorsNature200040725826411001069
   PubMed Web of Science ®Google Scholar
• AndersenHGreenbergDLFujikawaKXuWChungDWDavieEWProtease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activityProc Natl Acad Sci U S A199996111891119310500152
   PubMed Web of Science ®Google Scholar
• CookJJSitkoGRBednarBAn antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkeyCirculation199591296129717796507
   PubMed Web of Science ®Google Scholar
• CoughlinSRProtease-activated receptors in hemostasis, thrombosis and vascular biologyJ Thromb Haemost200531800181416102047
   PubMed Web of Science ®Google Scholar
• ChintalaMStronyJYangBKurowskiSLiQSch 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a folts model of arterial thrombosis in cynomolgus monkeysArterioscler Thromb Vasc Biol2010302143214920798382
   PubMed Web of Science ®Google Scholar
• ChackalamannilSWangYGreenleeWJDiscovery of a novel, orally active himbacine-based thrombin receptor antagonist (sch 530348) with potent antiplatelet activityJ Med Chem2008513061306418447380
   PubMed Web of Science ®Google Scholar
• GhosalALuXPennerNIdentification of human liver cytochrome p450 enzymes involved in the metabolism of sch 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonistDrug Metab Dispos201139303820926621
   PubMed Web of Science ®Google Scholar
• Zontivity™ (vorapaxar) tablets 2.08 mg*, for oral use *equivalent to 2.5 mg vorapaxar sulfateKenilworth, NJMerck Sharp & Dohme Corp (MSD)2014
   Google Scholar
• KosoglouTKraftWKKumarBPharmacokinetics and pharmacodynamics of the novel par-1 antagonist vorapaxar in patients with end-stage renal diseaseEur J Clin Pharmacol2012681049105622315147
   PubMed Web of Science ®Google Scholar
• EdelsteinLCSimonLMLindsayCRCommon variants in the human platelet par4 thrombin receptor alter platelet function and differ by raceBlood20141243450345825293779
   PubMed Web of Science ®Google Scholar
• BeckerRCMoliternoDJJenningsLKSafety and tolerability of sch 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase ii studyLancet200937391992819286091
   PubMed Web of Science ®Google Scholar
• GotoSYamaguchiTIkedaYKatoKYamaguchiHJensenPSafety and exploratory efficacy of the novel thrombin receptor (par-1) antagonist sch530348 for non-st-segment elevation acute coronary syndromeJ Atheroscler Thromb20101715616420124733
   PubMed Web of Science ®Google Scholar
• TricociPHuangZHeldCThrombin-receptor antagonist vorapaxar in acute coronary syndromesN Engl J Med2012366203322077816
   PubMed Web of Science ®Google Scholar
• JonesWSTricociPHuangZVorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (tracer)Am Heart J201416858859625262270
   PubMed Web of Science ®Google Scholar
• JenningsLKMechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosisThromb Haemost200910224825719652875
   PubMed Web of Science ®Google Scholar
• MorrowDABraunwaldEBonacaMPVorapaxar in the secondary prevention of atherothrombotic eventsN Engl J Med20123661404141322443427
   PubMed Web of Science ®Google Scholar
• MorrowDASciricaBMFoxKAEvaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (tra 2 degrees p)-timi 50 trialAm Heart J2009158335341.e33319699854
   PubMed Web of Science ®Google Scholar
• MehranRRaoSVBhattDLStandardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortiumCirculation20111232736274721670242
   PubMed Web of Science ®Google Scholar
• CavenderMASciricaBMBonacaMPVorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-timi 50 trialCirculation20151311047105325681464
   PubMed Web of Science ®Google Scholar
• BonacaMPSciricaBMCreagerMAVorapaxar in patients with peripheral artery disease: results from tra2{degrees}p-timi 50Circulation2013127152215291529e1623501976
   PubMed Web of Science ®Google Scholar
• IakovouISchmidtTBonizzoniEIncidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stentsJAMA20052932126213015870416
   PubMed Web of Science ®Google Scholar
• BonacaMPSciricaBMBraunwaldECoronary stent thrombosis with vorapaxar versus placebo: results from the tra 2 degrees p-timi 50 trialJ Am Coll Cardiol2014642309231725465416
   PubMed Web of Science ®Google Scholar
• MauriLHsiehWHMassaroJMHoKKD’AgostinoRCutlipDEStent thrombosis in randomized clinical trials of drug-eluting stentsN Engl J Med20073561020102917296821
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med201236691922077192
   PubMed Web of Science ®Google Scholar
• WindeckerSKolhPAlfonsoF2014 esc/eacts guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Eur Heart J2014352541261925173339
   PubMed Web of Science ®Google Scholar
• StegPGJamesSKAtarDEsc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevationEur Heart J2012332569261922922416
   PubMed Web of Science ®Google Scholar